May 19, 2021
A new bioresorbable scaffold (Firesorb, MicroPort Medical), one with much thinner struts compared with first-generation “dissolving” devices, has shown some early promise in a study of patients with relatively simple coronary artery lesions.
Presenting the results of FUTURE II as a late-breaking clinical trial at EuroPCR, Bo Xu, MBBS (National Clinical Research Center for Cardiovascular Disease/Peking Union Medical College, Beijing, China), reported that in this trial, which included operators adhering to a dedicated implantation technique, the bioresorbable scaffold was noninferior to a cobalt-chromium everolimus-eluting stent (Xience; Abbott Vascular) for the primary endpoint of in-segment late lumen loss.
While FUTURE II is a small study looking solely at angiographic outcomes, Xu said he remains optimistic about the technology. “I think, although this is a very small sized study with angiographic outcomes is comparing a new device with a drug-eluting ste
The creation of thirty new jobs in Galway by Enterprise Ireland Companies is a huge boost for the West of Ireland, according to Senator for Roscommon-Galway, Aisling Dolan who is Seanad Spokesperson for Further & Higher Education, Science, Innovation and Research.